RDY 6-K 2026 - Equibles

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit<br><br> <br>Number	Description of Exhibits
99.1	Intimation dated July 23, 2026

| 2 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED<br><br> <br>(Registrant)
Date: July 23, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

| 3 |

| --- |

Exhibit 99.1

	Dr. Reddy’s Laboratories Ltd.<br><br> <br>8-2-337,<br> Road No. 3, Banjara Hills<br><br> <br>Hyderabad<br> – 500 034, Telangana, India<br><br> <br><br><br> <br>CIN:<br> L85195TG1984PLC004507<br><br> <br><br><br> <br>Tel:<br> + 91 40 4900 2900<br><br> <br>Fax:<br> + 91 40 4900 2999<br><br> <br>Email:<br> [email protected]<br><br> <br>Web:<br> www.drreddys.com

July 23, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Sub:	Disclosureunder Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing RegulationsRegulations’)

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations and in furtherance to our intimation dated May 12, 2026, we hereby inform that, the members of the Company at the 42^nd^ Annual General Meeting (‘AGM’) held today, have approved the following resolutions with requisite majority:

1.	Re-appointment of Dr. K P Krishnan (DIN: 01099097) as an Independent Director

Approved re-appointment of Dr. K P Krishnan (DIN: 01099097) as an Independent Director for a second term of five consecutive years from January 7, 2027 to January 6, 2032, not liable to retire by rotation.

Dr. Krishnan is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. He meets the criteria for being re-appointed as an Independent Director under the applicable laws.

2.	Appointment of Mr. Srikanth Velamakanni (DIN: 01722758) as an Independent Director

Approved appointment of Mr. Srikanth Velamakanni (DIN: 01722758) as an Independent Director, for a term of five consecutive years, from July 1, 2026 to June 30, 2031, not liable to retire by rotation.

Mr. Srikanth is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. He meets the criteria for being appointed as an Independent Director under the applicable laws.

3.	Appointment of M/s Deloitte Haskins & Sells, LLP, Chartered Accountants as Statutory Auditors

Approved appointment of M/s Deloitte Haskins & Sells, LLP, Chartered Accountants (Firm Registration No. 117366W/W-100018), as the Statutory Auditors of the Company, for a term of five consecutive years, commencing from the conclusion of the 42^nd^ AGM till the conclusion of the 47^th^AGM.

The disclosures required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are attached as Annexures.

This is for your information and records.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

CompanySecretary, Compliance Officer & Head-CSR

Encl: as above

Detailsof Dr. K P Krishnan (DIN: 01099097)

Sl.no.	Particulars	Details
1.	Reason<br> for change viz. ~~appointment,~~ re-appointment~~, resignation, removal, death or otherwise~~	Re-appointment
2.	Date<br> of ~~appointment~~/re-appointment/~~cessation~~ (as applicable) & term of ~~appointment~~/re-appointment	Re-appointment<br>of Dr. K P Krishnan (DIN: 01099097) as an Independent Director of the Company for a second term of five consecutive years from January<br>7, 2027 to January 6, 2032, not liable to retire by rotation.
3.	Disclosure<br> of relationships between directors (in case of appointment of a director)	Dr.<br>K P Krishnan is not related to any of the Directors of the Company

BriefProfile of Dr. Krishnan:

Dr. K.P. Krishnan is a former IAS officer with 37 years of distinguished service in public policy, economic governance, and regulatory reform across the Government of India, Government of Karnataka, and the World Bank. He has held key national leadership roles, including Secretary, Ministry of Skill Development and Entrepreneurship; Additional/Special Secretary in the Ministries of Finance and Rural Development; and Secretary to the Prime Minister’s Economic Advisory Council.

A respected academician, he has taught at IIM Bangalore, ISB, and Ashoka University, held the Bok Visiting Professorship at the University of Pennsylvania Law School, and served as IEPF Chair Professor at NCAER, New Delhi. He is currently a Distinguished Fellow at the Isaac Centre for Public Policy, Ashoka University.

Dr. Krishnan serves on the boards and advisory councils of several leading corporates and non-profits, including Dr. Reddy’s Laboratories, Tata Consumer Products, Shriram Capital, ASREC India, Helios Trustee, Razorpay, and the Sanmar Group. He holds degrees in Economics (St. Stephen’s College), Law (Campus Law Centre, University of Delhi), and a Ph.D. in Economics (IIM Bangalore).

Detailsof Mr. Srikanth Velamakanni (DIN: 01722758)

Sl.no.	Particulars	Details
1.	Reason<br> for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	Appointment
2.	Date<br> of appointment/~~re-appointment/cessation~~ (as applicable) & term of appointment/re-appointment	Appointment<br>of Mr. Srikanth Velamakanni (DIN: 01722758) as an Independent Director for a term of five consecutive years, effective from July 1, 2026<br>to June 30, 2031.
3.	Disclosure<br> of relationships between directors (in case of appointment of a director)	Mr.<br>Srikanth Velamakanni is not related to any of the Directors of the Company

BriefProfile: Mr. Srikanth Velamakanni

Mr. Srikanth Velamakanni is one of India’s most influential technology leaders and a global champion of artificial intelligence. He is the Co-Founder and Group Chief Executive of Fractal, India’s first publicly listed pure-play AI company. He also serves as the Chairperson of Nasscom and as a Founder-Trustee of Plaksha University. Srikanth’s work is guided by a long-term commitment to building technology that expands human potential.

Detailsof Statutory Auditors

Sl.no.	Particulars	Details
1.	reason<br> for change viz. appointment, re-appointment, ~~resignation, removal, death or otherwise~~	Appointment
2.	Date<br> of appointment/~~re-appointment/cessation~~ (as applicable) & term of appointment/re-appointment	Appointment<br>of M/s Deloitte Haskins & Sells, LLP, Chartered Accountants (Firm Registration No. 117366W/W-100018), as the Statutory Auditors of<br>the Company, for a term of five consecutive years, commencing from the conclusion of the 42^nd^ Annual General Meeting (AGM)<br>till the conclusion of the 47^th^ AGM.
3.	Brief<br> profile (in case of appointment)	Deloitte<br>Haskins & Sells, Mumbai was constituted in 1997 and has been converted to a Limited Liability Partnership (LLP), with the name Deloitte<br>Haskins & Sells LLP (““DHS LLP”” or ““Firm””), w.e.f. November 20, 2013. DHS LLP<br>is registered with the Institute of Chartered Accountants of India (Registration No. 117366W/W-100018) and is a part of Deloitte Haskins<br>& Sells & Affiliates being the Network of Firms registered with the ICAI. The registered office of the Firm is One International<br>Center, Tower 3, 31st Floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai - 400013, Maharashtra, India.
4.	Disclosure<br> of relationships between directors (in case of appointment of a director)	Not<br> applicable